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INTRODUCTION
Several sympathomimetic drugs are used as topical nasal 
decongestants. These drugs are commonly classified into 
sympathomimetic amines (e.g.,  phenylephrine and ephed-
rine) and imidazolines (e.g., oxymetazoline and xylometazo-
line). It is assumed that the both classes induce a decongestant 
effect through the activation of α-adrenoceptors in the nasal 
vasculature. Topical decongestants are short-term effective in 
relieving nasal congestion, a prominent symptom associated 
with conditions such as common cold, allergic rhinitis, sinus-
itis or otitis media [1]. However, due to their indiscriminate 
use there is a risk of development of rebound congestion or 
rhinitis medicamentosa [2]. The risk of such a serious compli-
cation may be prevented or at least delayed using a polyphar-
macological, as opposed to single-target approach, aimed to 
optimize the therapeutic outcome by concomitant modula-
tion of multiple rather than single drug targets [3,4].
Basic research data suggest that imidazoline deconges-
tants act not only through the α-adrenergic but also through 
serotonin 5-hydroxytryptamine (5-HT) receptors [5-7]. 
Thus, both oxymetazoline and xylometazoline have been 
recognized as high-affinity, high-efficacy 5-HT2B receptor 
agonists  [8]. Although not specifically linked to imidazo-
line decongestants, activation of these receptors may cause 
vasoconstricting effects, and is also associated with a risk for 
drug-induced valvular heart disease [8,9]. On the contrary, 
the activation of other receptors could be a potential ben-
efit of nasal decongestants. For example, the 5-HT1B recep-
tors are expressed in human nasal mucosa and possibly play 
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ABSTRACT
Lerimazoline is a sympathomimetic drug that belongs to the imidazoline class of compounds, and is used as a nasal decongestant. Studies on 
lerimazoline are rare, and its pharmacological profile is not completely understood. Here, we analyzed the affinity of lerimazoline for dopamine 
receptor D2, serotonin 5-HT1A and 5-HT2A receptors and α1-adrenoceptor, and investigated lerimazoline contractile effects in isolated rat tho-
racic aorta. We also determined the effect of several antagonists on the contractile response to lerimazoline, including prazosin (α1-adrenocep-
tor antagonist), RX 821002 and rauwolscine (α2-adrenoceptor antagonists), JP 1302 (α2C-adrenoceptor antagonist), methiothepin (non-selective 
5-HT receptor antagonist), SB 224289 (5-HT1B receptor antagonist), BRL 15572 (5-HT1D receptor antagonist), and ketanserin (5-HT2A receptor 
antagonist). Lerimazoline displayed high affinity for the 5-HT1A receptor (Ki = 162.5 nM), similar to the previously reported affinity for the 
5-HT1D receptor. Binding affinity estimates (Ki) for α1, 5-HT2A, and D2 receptors were 6656, 4202 and 3437.5 nM, respectively (the literature 
reported Ki for 5-HT1B receptor is 3480 nM). Lerimazoline caused concentration-dependent contractions in 70% of preparations, varying in the 
range between 40% and 55% of the maximal contraction elicited by phenylephrine. While prazosin reduced the maximum contractile response 
to lerimazoline, rauwolscine showed a non-significant trend in reduction of the response. Both ketanserin (10 nM and 1 µM) and methiothepin 
strongly suppressed the maximum response to lerimazoline. Overall, our results suggest that 5-HT2A and, less distinctly, α1-adrenergic receptors 
are involved in the lerimazoline-induced contractions, which makes lerimazoline an “atypical” decongestant.
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sympathomimetic drug
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a role in the regulation of nasal airway resistance and nasal 
secretion [10].
Lerimazoline is the international nonproprietary name 
recently adopted for 2-[(2,4,6-trimethylphenyl)meth-
yl]-4,5-dihydro-1H-imidazole, a congener of oxymetazoline 
and xylometazoline, originally patented in 1963 [11,12]. In 
combination with phenylephrine, this sympathomimetic drug 
of the imidazoline class, has been used as a nasal deconges-
tant for decades in several countries, in the concentration 
of 2.1 × 10-6 M for children and 6.3 × 10-6 M for adults [13]. 
However, the primary research studies on this compound, 
reported earlier as St-71, trimizoline or trimazoline, are 
scarce  [14-17] and its pharmacological profile is not com-
pletely understood. While lerimazoline has a substantial affin-
ity for the 5-HT1D and much lower affinity for 5-HT1B receptors 
(Ki values 72 versus 3480 nM) [6], its affinity for other 5-HT 
or α-adrenergic receptors has not been specifically examined. 
Importantly, Law et al. [6] evaluated lerimazoline for contrac-
tile activity in the rings of rabbit saphenous vein and found 
that it induces contractions in an α-adrenoceptor - and pros-
taglandin-independent manner [6].
Here, we analyzed the affinity of lerimazoline for the dopa-
mine receptor D2, 5-HT1A and 5-HT2A receptors and α1-adre-
noceptor, and investigated lerimazoline contractile effects 
in isolated rat thoracic aorta [18,19]. We also determined 
the effect of eight antagonists on the contractile response to 
lerimazoline.
MATERIALS AND METHODS
Membrane preparation, radioligand binding assays, 
and data analysis
Specific binding affinities were determined as described 
previously [20] by measuring the extent of displacement of 
[3H] labelled specific ligands, purchased from Perkin Elmer 
LAS GmbH, (Rodgau, Germany). A range of concentrations 
(10–4 to 10–10 M) of [3H] Spiperone [specific activity (spec. 
act.) 73.36 Ci mmol–1], 8-Hydroxy-[3H] DPAT (spec. act.142 
Ci mmol–1), [3H] Ketanserin (spec. act. 47.3 Ci mmol–1) and 
[3H] Prazosin (spec. act. 81.7 Ci mmol–1) were used to label 
the D2, 5-HT1A, 5-HT2A and α1-adrenoceptor, respectively, 
from rat striatal or cortical synaptosomes. Nonspecific bind-
ing was measured in the presence of 10 µM of spiperone (D2), 
10 µM of buspirone (5-HT1A), 10 µM of ketanserin (5-HT2A), 
and 10 µM of prazosin (α1). The tubes (0.4 ml total volume of 
the incubation mixture for D2 receptor and 0.2 ml total vol-
ume of the incubation mixture for 5HT1A, 5-HT2A, and α1-ad-
renergic receptor) were incubated for 10 minutes at 37°C, and 
the reaction was terminated by vacuum filtration through 
Whatman GF/C filters. The filters were washed two times 
with 5.0 ml ice-cold incubation buffer. Retained radioactivity 
was measured by introducing dry filters and 4  ml of tolu-
ene-based scintillation liquid and counting in a LKB Wallac 
1219 RackBeta Flexi-Vial Spectral Liquid Scintillation Counter 
(EG&G Wallac, Turku, Finland). Competition binding curves 
were constructed and analyzed by GraphPad Prism v. 4.0 
(GraphPad Software, Inc., San Diego, CA, USA).
Chemicals and drugs
Lerimazoline hydrochloride and phenylephrine hydro-
chloride were kindly donated from Zdravlje Actavis, 
Leskovac, Serbia. SB 224289 (5-HT1B receptor antagonist), BRL 
15572 (5-HT1D receptor antagonist) and RX 821002 hydrochlo-
ride (α2-adrenoceptor antagonist) were purchased from Tocris 
(Bristol, UK). Ketanserin tartrate (5-HT2A receptor antagonist), 
methiothepin hydrochloride (non-selective 5-HT receptor 
antagonist), prazosin hydrochloride (α1-adrenoceptor antago-
nist), rauwolscine hydrochloride (α2-adrenoceptor antagonist) 
and JP 1302 hydrochloride (α2C-adrenoceptor antagonist) were 
purchased from Sigma Aldrich (St. Louis, MO, USA).
All ligands, except SB 224289, BRL 15572 and JP 1302, were 
prepared as concentrated stock solutions in distilled water 
before diluting to final volume, and stored at 4°C during the 
experiment. SB 224289, BRL 15572 and JP 1302 were initially 
dissolved in 1% dimethyl sulfoxide (DMSO) and subsequent 
dilutions were carried out in distilled water. Drug concentra-
tions are described as final molar concentrations (mol/liter) 
in the tissue bath. At the volumes used, none of the vehicles 
showed pharmacological activity in the blood vessels.
Experimental animals
Adult male Wistar rats weighing 250-400 g were obtained 
from Military Farm, Belgrade, Serbia. All experimental proce-
dures were approved by the Ethical Commission on Animal 
Experimentation of the Faculty of Pharmacy in Belgrade and 
were carried out in accordance with the EEC Directive 86/609. 
Rats were housed in clean transparent plastic cages with free 
access to tap water and pelleted food, and kept in a conventional 
animal facility at a temperature of 22 ± 1°C, relative humidity of 
40-70% and the 12 hours light period, with lights on from 06:00.
Preparation of the rat aortic rings
Male Wistar rats were euthanized with carbon dioxide 
(CO2) and the thoracic aortas were isolated. Tissues were 
placed thereafter in Petri dishes containing modified Krebs 
bicarbonate buffer, cleared of adhering fat and connective 
tissue, and cut into cylindrical segments with a length of 
~ 2-3 mm. In a number of vessel preparations, the endothe-
lial cell layer was removed by gently rubbing the luminal sur-
face of the ring. The prepared aortic rings were then placed in 
an organ bath containing 25 ml of Krebs-Ringer bicarbonate 
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buffer consisting of 118.3 mM NaCl, 4.7 mM KCl, 2.5 mM 
CaCl2, 1.2 mM MgSO4 × 7H2O, 25 mM NaHCO3, 1.2 mM 
KH2PO4 and 11 mM glucose, maintained at 37°C, pH 7.4, con-
tinuously bubbled with 95% O2 and 5% CO2.
Two stainless steel triangles were placed through the 
lumen of the aortic rings, one was connected to the tissue 
chamber and the other to the MLT0201 force displacement 
transducer (Panlab, Spain). The signal was digitized using 
the Powerlab/4SP data acquisition system (ADInstruments, 
Castle Hill, Australia) and changes in isometric tension were 
recorded with LabChart 6 Pro software (AD Instruments).
Segments were allowed to equilibrate for 1 hour in Krebs 
bicarbonate buffer solution, and the solution was replaced 
every 10  minutes to prevent the accumulation of metabolic 
end products. During the next 10  minutes, each aortic ring 
was stretched progressively to a length optimal for maximal 
isometric contraction (2  g, as determined in preliminary 
experiments). Additionally, the rings were allowed to equili-
brate for 30-40 minutes before commencing the experiment.
Experimental protocols
In the first series of experiments, endothelial integrity was 
examined by inducing the contraction of the rat aorta with 
phenylephrine (10-4 M) followed by the addition of acetylcho-
line (10-5 M). A preparation was considered to have endothe-
lium when the relaxation evoked by acetylcholine was at least 
70%. Thereafter, cumulative concentration-response curves 
(CCRCs) to lerimazoline (concentration range: 10-7-3 × 10-4 M) 
were obtained in the rings, previously equilibrated to the basal 
tone. CCRCs were generated by increasing the concentration 
of lerimazoline in half-log increments, once the constriction 
to the previous concentration had stabilized [21,22]. After a 
wash out period of 30 minutes, the entire procedure has been 
replicated to confirm that repeated exposure of aortic rings to 
lerimazoline in the absence of any antagonist evoked similar 
constrictor responses (data not shown).
In the second series of experiments, each equilibrated 
rat aorta was first constricted by incremental concentrations 
of lerimazoline (10-7-3 × 10-4 M). After a wash out period of 
30  minutes during which Krebs-Ringer Bicarbonate Buffer 
(KRB) buffer was replaced every 10  minutes and the rings 
returned to the baseline tension, SB 224289  (10-6 M), BRL 
15572 (10-6 M), ketanserin tartrate (10-8 and 10-6 M), prazosin 
hydrochloride (3 × 10-7 M), RX 821002 (3 × 10-9 M), rauwols-
cine hydrochloride (10-7 M) or JP 1302  (10-5 M) were added 
to the bath and incubated for 20  minutes, before obtaining 
the CCRCs to lerimazoline in the presence of the respective 
antagonist. At the end of each experiment, the aortic rings 
were additionally equilibrated for 30  minutes to the resting 
tension and finally contracted with phenylephrine (10-4 M). 
The strength of constriction was expressed as a percentage of 
the maximum tension induced by lerimazoline compared to 
that induced by phenylephrine (10-4 M). Each segment of the 
rat aorta was used only for one experimental protocol.
Statistical analysis
Lerimazoline-evoked contractile responses were 
expressed as mean ± standard error of the mean (SEM) for 
number (n) of observations, where n equals the number of 
animals from which aortic rings were isolated. Contraction in 
each tissue was reported as a percentage of control response 
to phenylephrine (10-4 M). The potency of the agonist was 
measured in terms of EC50 for each curve (the given concen-
tration of lerimazoline was required to produce 50% of the 
calculated maximum response for the agonist) and presented 
as pEC50 (the negative log10 of the EC50 value) by using soft-
ware LabChart 7 (ADInstruments). Antagonist potency was 
expressed as an apparent pKb value calculated according to 
the following equation:
pKb = log(DR-1) - log[B],
where DR is the ratio of the mean EC50 value in the pres-
ence of the antagonist to the mean EC50 value in the absence of 
the antagonist; B is the molar concentration of the antagonist 
tested.
Statistical analysis of CCRCs was performed by unpaired 
Student’s t Test when comparing two groups, or by analysis of 
variance (ANOVA) followed by the Student-Newman-Keuls 
post hoc test in the case of three or more groups. In all cases, 
a p value less than 0.05 was considered statistically significant. 
Using SigmaPlot 11 (Systat Software Inc., Richmond, USA) 
software, a linear regression analysis of published pooled bind-
ing data for the analyzed antagonists of α-adrenergic and sero-
tonergic receptors in humans (or if available in the rat) and our 
pKb values was conducted [23-25]. At least three pairs of valid 
data were necessary to generate correlation for a given recep-
tor subtype; if an antagonist acted as a full agonist on a sec-
ondary receptor, the data were not included into the analysis.
RESULTS
Binding study
Binding affinities (Ki) of lerimazoline for four examined 
receptor types (D2, 5-HT1A, 5-HT2A, and α1-adrenoceptor) are 
presented in Table  1. Among these receptors, lerimazoline 
displayed the highest submicromolar affinity for the 5-HT1A 
receptor.
Vascular effects of lerimazoline
Lerimazoline caused concentration-dependent con-
tractions of rat aorta rings in approximately 70% of tested 
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preparations, in the concentration range 3 × 10-6-3 × 10-4 M; 
in the rest of aorta preparations, the response was either weak 
(less than 15% of the maximal effect elicited by phenyleph-
rine) or absent. The results obtained from all 75 aorta prepa-
rations (one piece of each aorta from 75 different animals) 
that responded to lerimazoline, irrespective of the presence 
of endothelium, are given in Table  2. When vasoactive, leri-
mazoline produced mean maximal contractions varying in 
the range between 40% and 55% of the contractions elicited 
by 10-4 M phenylephrine (Emax: 45.08 ± 1.18% of 10
-4 phenyl-
ephrine maximal contraction; pEC50:  4.30, n = 75; the pEC50 
of phenylephrine was 5.77). Thus, lerimazoline appear to be 
a less potent and less effective contractile agent compared to 
phenylephrine. The effect of lerimazoline was not dependent 
on the endothelium, i.e.,  there was no statistical difference 
between the results obtained in the rat aortas with and with-
out the endothelium (Figure 1). Noticeably, the concentration 
response curves to lerimazoline showed that the receptors 
were not saturated at 3 × 10-4 M. However, a number of exper-
iments using additional concentrations (1 × 10-3 and 3 × 10-3 
M) revealed that the concentration response curve to lerima-
zoline cannot reach the plateau phase (due to a decrease ten-
dency of the contractile response; data not shown) and thus 
the maximal contraction to lerimazoline was set at 3 × 10-4 M.
Contractile effects of lerimazoline in the absence 
and presence of α-adrenoceptor antagonists
To examine the involvement of noradrenergic (α1-  and 
α2-adrenoceptor) and serotonergic systems in lerimazoline-in-
duced contraction, selective α-adrenoceptor and serotonergic 
antagonists were used in the rat aortas (Table 3).
Prazosin (0.3 µM), an α1-adrenoceptor antagonist, signifi-
cantly reduced the maximum contractile response to lerima-
zoline (Emax: 44.83 ± 3.28% in the absence versus 27.83 ± 5.32% in 
the presence of prazosin, p < 0.05, Figure 2A; n = 15). Although 
prazosin caused a rightward shift in the concentration-re-
sponse curve to lerimazoline, we were not able to calculate the 
pKb value because DR was less than 1.
RX 821002 (30 nM, pKb = 8.19), an α2-adrenoceptor antag-
onist, did not affect significantly the contractile response to 
TABLE 1. Binding affinities of lerimazoline to different 
receptors. For convenience, the published data for lerimazoline 
at serotonin 5-HT
1D
 and 5-HT
1B
 receptors [6] were also 
reproduced (designated with an asterisk)
Receptor Ki±SEM (nM)
Dopamine D2 3437.5±138.9
Serotonin 5-HT1A 162.5±4.5
Serotonin 5-HT2A 4202±78
α1-adrenoceptor 6656±149
Serotonin 5-HT1D* 72±12
Serotonin 5-HT1B*  3480±1690
*Published in Law et al. [6]; SEM: Standard error of the mean
TABLE 2. Effects of lerimazoline on the constriction of rat thoracic 
aorta
Lerimazoline (M) Constriction (%)
1×10−7 −3.07±0.38
3×10−7 −1.70±0.49
1×10−6 −0.86±0.56
3×10−6 1.68±0.73
1×10−5 5.69±0.93
3×10−5 16.42±1.25
1×10−4 29.80±1.34
3×10−4 45.08±1.18
The strength of constriction is expressed as a percentage of the 
maximum tension induced by lermazoline compared to that induced by 
10−4 M phenylephrine. Data are expressed as mean±standard error of the 
mean (SEM), n=75
TABLE 3. Effect of prazosin, RX 821002, rauwolscine, JP 1302, 
ketanserin, methiothepin, SB 224289, and BRL 15572 on the 
contractions of rat thoracic aorta induced by lerimazoline
Drug pEC50 n Concentration (µM)
PRAZOSIN
Untreated
Treated
3.93±0.09
4.01±0.24
15 0.3
RX 821002
Untreated
Treated
3.91±0.26
3.15±0.27
12 0.03
PRAZOSIN+RX 821002
Untreated
Treated
3.45±0.16
3.51±0.37
8 0.3
0.03
JP 1302
Untreated
Treated
4.07±0.11
3.98±0.35
9 1
RAUWOLSCINE
Untreated
Treated
4.13±0.13
3.69±0.11
10 0.1
METHIOTHEPIN
Untreated
Treated
4.30±0.13
3.99±0.34
9 0.3
BRL 15572
Untreated
Treated
3.85±0.14
3.77±0.21
12 1
SB 224289
Untreated
Treated
4.24±0.08
3.98±0.08
10 1
KETANSERIN
Untreated
Treated
4.42±0.24
3.80±0.27
9 1
KETANSERIN
Untreated
Treated
4.02±0.31
3.89±0.38
7 0.01
Values are expressed as mean±standard error of the mean (SEM); pEC
50
 
is the negative log of lerimazoline concentrations inducing 50% of the 
maximum contractile response
lerimazoline (Emax: 40.92 ± 3.65% in the absence versus 35.45 ± 6.31% 
in the presence of RX 821002, p > 0.05, Figure 2B; n = 12).
An additional set of experiments was carried out with 
a combination of prazosin (0.3 µM) and RX 821002  (30 
nM). The combination of two drugs reduced the maximum 
response to lerimazoline to similar extent as prazosin (Emax: 
48.72 ± 4.86% in the absence versus 28.81 ± 6.80% in the pres-
ence of prazosin and RX 821002, p < 0.05, Figure 2C; n = 8). As 
in the former analysis, we were not able to calculate the pKb 
value (pEC50 value for lerimazoline was 3.45 ± 0.16, while for 
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the combination of prazosin and RX 821002 it was 3.51 ± 0.37; 
p > 0.05).
Next, we examined the effect of the nonselective α2-adre-
noceptor antagonist rauwolscine and α2C-adrenoceptor antag-
onist JP 1302 on the isolated rat aorta. While JP 1302 (1 µM; pKb 
= 5.4) did not significantly affect the lerimazoline-induced con-
traction (Emax: 37.85 ± 4.03% in the absence versus 36.39 ± 5.23% 
in the presence of JP 1302; Figure 3B; n = 9), rauwolscine (0.1 
µM; pKb = 7.23) caused a rightward shift in the concentra-
tion-response curve to lerimazoline, but the result was not sig-
nificant (38.82 ± 3.98 in the absence versus 27.66 ± 4.14% in the 
presence of rauwolscine, p = 0.067, Figure 3A; n = 10).
Contractile effects of lerimazoline in the absence 
and presence of serotonergic antagonists
Methiothepin (a non-selective serotonergic antagonist, 30 
nM; pKb = 7.53) strongly suppressed the maximum response 
to lerimazoline [Emax: 46.26 ± 6.06% in the absence versus 
14.58 ± 5.57% in the presence of methiothepin, p < 0.01] (Figure 4).
The effects of the selective 5-HT1B, 5-HT1D, and 5-HT2A 
antagonists are shown in Figure  5. 5-HT1D antagonist BRL 
15572 did not block the response to lerimazoline at 1 µM 
(pKb = 5.28; Emax: 43.63 ± 3.58% in the absence versus 33.73 ± 
7.02% in the presence of BRL 15572, p > 0.05, Figure 5A; n = 12), 
similarly, the maximum contractile response to lerimazoline 
was not suppressed by 5-HT1B antagonist SB 224289 at 1 µM 
(pKb = 5.92; Emax: 38.04 ± 3.61% in the absence versus 33.61 ± 
6.12% in the presence of SB 224289, p > 0.05, Figure 5B; n = 10).
Since the rat thoracic aorta is an established model for 
5-HT2A receptor-mediated contraction [26], we examined the 
effect of ketanserin at two concentrations: 10 nM (pKb = 7.53) 
and 1 µM (pKb = 6.51). At 1 µM concentration, ketanserin 
FIGURE 1. Concentration-response curves for phenylephrine 
(n=12) and lerimazoline (n=38) in the rat aorta with and without 
endothelium. Values are expressed as mean±standard error of the 
mean (SEM). The strength of constriction is expressed as a per-
centage of the maximum tension induced by lerimazoline to that 
induced by 10-4 M phenylephrine. The removal of the endothe-
lium did not affect the contraction induced by lerimazoline.
FIGURE 2. Effects of (A) α
1
-adrenoceptor antagonist prazosin (0.3 µM, n=15), (B) α
2
-adrenoceptor antagonist RX 821002 (30 nM, n=12) 
and (C) the combination of prazosin and RX 821002 (n=9) on lerimazoline-induced contraction in the rat aorta. The points represent 
mean±standard error of the mean (SEM). The strength of constriction is expressed as a percentage of the maximum tension induced by 
lerimazoline to that induced by 10-4 M phenylephrine. The effects of the antagonist(s) on the lerimazoline-induced constrictions were 
compared with the control (*p<0.05, Student’s t-test).
C
BA
199
Eldina Rizvić, et al.: Lerimazoline contracts rat aorta mainly through 5-HT2A receptors
significantly inhibited lerimazoline-evoked vasoconstriction 
[lerimazoline concentrations > 10 µM] (Figure 5C; n = 9); the 
Emax value was 37.15 ± 4.66% in the absence versus 19.25 ± 5.22% 
in the presence of 1 µM ketanserin, p < 0.05. Similar results were 
obtained for 10 nM concentration of ketanserin (Figure  5D; 
n = 7); the Emax value was 47.15 ± 3.14% in the absence versus 
19.07 ± 6.90% in the presence of 10 nM ketanserin, p < 0.01.
Correlation analysis with Ki values from the 
literature
Three or more pairs of valid data, necessary to determine 
linear correlation between Ki (literature data given in Table 4) 
and calculated pKb values were found for the four receptor 
subtypes; the analysis for 5-HT1D and 5-HT2A receptors was 
performed twice, involving separately the pKb values calcu-
lated for ketanserin at 10 nM and 1 µM concentration, respec-
tively. A  total of 6 correlations were obtained, but only one 
was statistically significant. For the 5-HT2A receptor a high and 
significant correlation with the literature values was observed 
only with the pKb value for 10 nM ketanserin (r = 0.997, 
n = 3, p = 0.049), but not with 1 µM of ketanserin (r = 0.729, 
n = 3, p = 0.480). A significant correlation was not observed for 
the α2C-adrenoceptor (r = 0.796, n = 3, p = 0.414), 5-HT1A recep-
tor (r = 0.906, n = 3, p = 0.278), and 5-HT1D receptor, when both 
pKb values of ketanserin were included (for 1 µM of ketanse-
rin r = 0.281, n = 5, p = 0.646; for 10 nM of ketanserin r = 0.257, 
n = 5, p = 0.676).
DISCUSSION
Although sympathomimetic properties of lerimazoline are 
well-known, the exact mechanism of action has been scarcely 
studied [14-17]. This imidazoline derivative binds with nano-
molar affinity to the human 5-HT1D receptors (Ki = 72 nM) and 
with micromolar affinity to the 5-HT1B receptors (Ki = 3480 
nM) [6]. In cells expressing recombinant 5-HT1B and 5-HT1D 
receptors lerimazoline markedly suppressed the forskolin-in-
duced increase in cAMP levels, which may be associated with 
its agonistic effects at both receptor subtypes [6].
Lerimazoline was also evaluated for contractile activity in 
the rings of rabbit saphenous vein pretreated with prazosin, 
idazoxan and indomethacin, in order to exclude its possible 
α1-, α2-adrenergic or prostaglandin-mediated effects, respec-
tively. The EC50 of lerimazoline (150 nM) was similar to that 
of the 5-HT1B/D receptor agonist sumatriptan (220 nM) [6]. 
In another study, treatment with sumatriptan, a 5-HT1D and 
5-HT1B receptor antagonist, in rabbit saphenous vein implied 
that contractile action of lerimazoline on this vein is predomi-
nantly associated with the activation of 5-HT1B receptors [27]. 
FIGURE 4. Effects of non-selective 5-HT-receptor antagonist 
methiothepin at the concentration of 0.3 µM (n=9) on the lerima-
zoline-induced contractions in the rat aorta. The points represent 
mean±standard error of the mean (SEM). The strength of con-
striction is expressed as a percentage of the maximum tension 
induced by lerimazoline to that induced by 10-4 M phenylephrine. 
The effects of the antagonist on the lerimazoline-induced con-
strictions were compared with the control (*p<0.05, ***p<0.001, 
Student’s t-test).
FIGURE 3. Effects of (A) non-selective α
2
-adrenoceptor antagonist rauwolscine (0.1 µM, n=10) and (B) α
2C
-adrenoceptor antagonist 
JP 1302 (1 µM, n=9) on the lerimazoline-induced contractions in the rat aorta. The points represent mean±standard error of the mean 
(SEM). The strength of constriction is expressed as a percentage of the maximum tension induced by lerimazoline to that induced by 
10-4 M phenylephrine. The effects of the antagonist on the lerimazoline-induced constrictions were compared with the control (*p<0.05, 
Student’s t-test).
BA
Eldina Rizvić, et al.: Lerimazoline contracts rat aorta mainly through 5-HT2A receptors
200
However, a relatively low affinity of lerimazoline for the 5-HT1B 
receptors in the study of Law et al. [6] does not correspond 
with this presumption.
In the present study, we selected rat thoracic aorta as a 
well-validated and widely used experimental model [18,19]. 
Lerimazoline caused contractions in the range between 40 
and 55% of the maximal contraction elicited by α1-adreno-
ceptor selective antagonist, phenylephrine, in an endothe-
lium-independent manner. The lerimazoline-induced con-
centration-dependent contractions, found in approximately 
70% of tested preparations, could be related to contractile 
activity of sumatriptan in preparations of some, but not all 
isolated human mesenteric arteries [28]. In our study, the 
binding profile of lerimazoline for the α1-adrenoceptor and 
5-HT receptor subtypes suggests that the 5-HT1A and 5-HT1D 
receptors are stimulated first, at concentrations close to 100 
nM. However, the contractile action of lerimazoline on the rat 
aorta started at concentrations close to 10 µM, indicating that 
some low-affinity binding sites are involved in the contractile 
response.
In the antagonist studies, we first examined whether 
the α1-  and α2-adrenoceptors are included in the contractile 
responses to lerimazoline. Lerimazoline-induced contractions 
were not affected by RX 821002, while they were inhibited by 
prazosin, with the change in the maximum response. To con-
firm that the α2-adrenoceptor is not involved in the contractile 
TABLE 4. Literature data on estimated binding affinities (Ki) of eight antagonists used in the study. The values obtained for linear 
regression analysis are given in bold
Receptor PRAZOSIN RX 821002 JP 1302 RAUWOLSCINE SB 224289 BRL 15572 KETANSERIN METHIOTHEPIN
α1-adrenoceptor 9.6 8.2 - - - - 8.2 -
α2-adrenoceptor - 9.2-9.5 - 8.4 - - - -
α2C-adrenoceptor 6.7-8.0 8.7 7.8 9.1 - - - -
Serotonin 5-HT1A - 24.55 - - - 7.7* - 7.8-8.1
Serotonin 5-HT1B - - - - 8.6* - - 7.1-8.5*
Serotonin 5-HT1D - - - 7.8 6.27 7.9 7.4-7.5 7.3-8.2*
Serotonin 5-HT2A - - - - 5.3 6.6** 8.6-9.0 8.5
Serotonin 5-HT2B - - - 7.8-8.4 - - - 8.7-9.2
Serotonin 5-HT2C - - - -  - - 6.8-7.5 8.4*
Serotonin 5-HT7 - - - - - - - 9.0-9.4
*Inverse agonist on specific type of receptor; **full agonist on specific type of receptor; Data as compiled by The British Pharmacological Society (BPS) 
and the International Union of Basic and Clinical Pharmacology (IUPHAR). Available from: http://www.guidetopharmacology.org
FIGURE 5. Effects of selective serotonergic antagonists: (A) 5-HT
1D
 antagonist BRL 15572 (1 µM, n=8), (B) 5-HT
1B
 antagonist SB 224289 (1 
µM, n=10), and (C and D) 5HT
2A
 antagonist ketanserin (1 µM, n=9; 10 nM, n=9) on the lerimazoline-induced contractions in the rat aorta. 
The points represent mean±standard error of the mean (SEM). The strength of constriction is expressed as a percentage of the maximum 
tension induced by lerimazoline to that induced by 10-4 M phenylephrine. The effects of the antagonist on the lerimazoline-induced 
constrictions were compared with the control (*p<0.05, **p<0.01; Student’s t-test.
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response, the concentration-response curve of lerimazoline 
was also analyzed in the presence of rauwolscine, a non-selec-
tive α2-adrenoceptor antagonist, and JP 1302, an α2C-adreno-
ceptor antagonist. Only rauwolscine produced displacement 
of the curve to the right, but without significantly changing the 
maximum contractile response to lerimazoline. Nevertheless, 
rauwolscine is also α1-adrenoceptor antagonist in rats, as 
demonstrated in radioligand binding studies using rat cerebral 
cortex, with a low selectivity value for the α2-adrenoceptor 
(5.5) [29]. Thus, our results with rauwolscine might be due to 
lerimazoline action at the α1- rather than at α2-adrenoceptor. 
Concordantly, intrahypothalamic injection of lerimazoline 
in rats, in doses up to 100 nmol, did not induce bradycardia, 
while clonidine, a selective α2-adrenoceptor agonist, induced 
bradycardia at a dose of 7 nmol [17]. However, the selective 
α1-adrenoceptor agonists phenylephrine and tramazoline also 
induced the bradycardic effects, though at higher doses (40 
nmol for both); in addition, oxymetazoline, a putative non-se-
lective α-adrenoceptor agonist, did not cause any effect at 
doses up to 100 nmol [17]. The described results could hardly 
be consistent if lerimazoline or oxymetazoline affects only the 
α-adrenoceptors.
Due to the observed inhibitory effect of methiothepin, a 
widely used non-selective 5-HT receptor antagonist, on the 
contractile response to lerimazoline, we performed additional 
experiments to investigate the possible involvement of the 
5-HT1A, 5-HT1B/1D, 5-HT2A, 5-HT2B or 5-HT2C receptors in the 
lerimazoline-induced contractions. The blood vessels were 
pretreated with BRL 15572 or SB 224289, selective antagonists 
at the 5-HT1D and 5-HT1B receptor, respectively. Neither BRL 
15572 nor SB 224289 reduced contraction to lerimazoline; 
the former, but not the latter finding is in agreement with the 
discussion above on the activity of lerimazoline on the rabbit 
saphenous vein [6]. As there are no data on the expression of 
5-HT1B receptors in the rat aorta, it is possible that this recep-
tor substrate was simply absent in the present model.
While both concentrations of ketanserin significantly 
reduced the contractile action of lerimazoline, we observed a 
significant positive correlation between literature Ki and our 
pKb values for the 5-HT2A receptor, when the values for 10 nM 
ketanserin were included, but not with the values obtained 
for 1 µM ketanserin. Previously, it was demonstrated that, at 
a lower concentration (10 nM), ketanserin antagonized only 
those receptors to which it has the highest affinity (pKi for 
the rat 5-HT2A was 8.6-9.0) [30], while at higher concentra-
tions it additionally antagonized the α1-adrenoceptor (pKi 7.8-
8.2) [31]. Given the similarities with our results for ketanserin, 
a predominance of the 5-HT2A over α1-adrenergic receptors 
may be assumed.
In conclusion, our results suggest that the mechanism of 
vasoconstrictor action of lerimazoline encompasses both, 
the activation of 5-HT2A, and to a lesser degree α1-adrener-
gic receptors. These results also suggest that lerimazoline is 
an “atypical” decongestant. Engaging multiple drug targets 
to achieve an optimal therapeutic outcome is a promising 
approach. Thus, the interactions of lerimazoline with phenyl-
ephrine as a standard decongestant should be further investi-
gated, especially with respect to rebound congestion, which 
may be overcome by a polypharmacological approach to 
administration of decongestants with different mechanisms 
of action.
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